Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

The Lancet

Volumn 392, Issue 10142, 2018, Pages 123-133

  Shitara, Kohei ^a   Özgüroğlu, Mustafa ^b,s   Bang, Yung Jue ^c,s   Di Bartolomeo, Maria ^d   Mandalà, Mario ^e   Ryu, Min Hee ^f,s   Fornaro, Lorenzo ^g   Olesiński, Tomasz ^h   Caglevic, Christian ⁱ   Chung, Hyun Cheol ^s   Muro, Kei ^k   Goekkurt, Eray ^l,m,s   Mansoor, Wasat ⁿ   McDermott, Raymond S ^o   Shacham Shmueli, Einat ^p,s   Chen, Xinqun ^q   Mayo, Carlos ^q   Kang, S Peter ^q   Ohtsu, Atsushi ^a   Fuchs, Charles S ^r   Lerzo, Guillermo ^s   O'Connor, Juan Manuel ^s   Mendez, Guillermo Ariel ^s   Lynam, James ^s   Tebbutt, Niall ^s   Wong, Mark ^s   Strickland, Andrew ^s   Karapetis, Chris ^s   Goldstein, David ^s   Vasey, Paul ^s   Van Laethem, Jean Luc ^s   Van Cutsem, Eric ^s   Berry, Scott ^s   Vincent, Mark ^s   Muller, Bettina ^s   Rey, Felipe ^s   Zambrano, Angela ^s   Guerra, Joaquin ^s   Krogh, Merete ^s   Baeksgaard, Lene ^s   Yilmaz, Mette ^s   Elme, Anneli ^s   Magi, Andrus ^s   Auvinen, Paivi ^s   Alanko, Tuomo ^s   Moehler, Markus ^s   Kunzmann, Volker ^s   Seufferlein, Thomas ^s   Thuss Patience, Peter ^s   Hoehler, Thomas ^s   Haag, Georg ^s   Al Batran, Salah Eddin ^s   Castro, Hugo ^s   Lopez, Karla ^s   Aguilar Vasquez, Mynor ^s   Sandoval, Mario ^s   Lam, Ka On ^s   Cuffe, Sinead ^s   Kelly, Cathy ^s   Geva, Ravit ^s   Hubert, Ayala ^s   Beny, Alex ^s   Brenner, Baruch ^s   Giuseppe, Aprile ^s   Falcone, Alfredo ^s   Maiello, Evaristo ^s   Passalacqua, Rodolfo ^s   Montesarchio, Vincenzo ^s   Hara, Hiroki ^s   Chin, Keisho ^s   Nishina, Tomohiro ^s   Komatsu, Yoshito ^s   Machida, Nozumo ^s   Hironaka, Shuichi ^s   Satoh, Taroh ^s   Tamura, Takao ^s   Sugimoto, Naotaoshi ^s   Cho, Haruhiko ^s   Omuro, Yashushi ^s   Kato, Ken ^s   Goto, Masahiro ^s   Hyodo, Ichinosuke ^s   Yoshida, Kazuhiro ^s   Baba, Hideo ^s   Esaki, Taito ^s   Furuse, Junji ^s   Wan Mohammed, Wan Zamaniah ^s   Hernandez Hernandez, Carlos ^s   Casas Garcia, Juan ^s   Dominguez Andrade, Adriana ^s   Clarke, Katriona ^s   Hjortland, Geir ^s   Glenjen, Nils ^s   Kubiatowski, Tomasz ^s   Jacek, Jassem ^s   Wojtukiewicz, Marek ^s   Lazarev, Sergey ^s   Lancukhay, Yuri ^s   Afanasayev, Sergey ^s   Moiseyenko, Vladimir ^s   Kostorov, Vladimir ^s   Protsenko, Svetlana ^s   Shirinkin, Vadim ^s   Sakaeva, Dina ^s   Fadeeva, Natalia ^s   Yong, Wei Peng ^s   Ng, Chau Hsien Matthew ^s   Robertson, Barbara ^s   Rapaport, Bernardo ^s   Cohen, Graham ^s   Dreosti, Lydia ^s   Ruff, Paul ^s   Jacobs, Conrad ^s   Landers, Gregory ^s   Szpak, Waldemar ^s   Roh, Sang Young ^s   Lee, Jeeyun ^s   Kim, Yeul Hong ^s   Alsina Maqueda, Maria ^s   Longo Munoz, Federico ^s   Cervantes Aguilar, Andres ^s   Aranda Aguilar, Enrique ^s   Garcia Alfonso, Pilar ^s   Rivera, Fernando ^s   Feliu Batle, Jaime ^s   Pazo Cid, Roberto ^s   Yeh, Kun Huei ^s   Chen, Jen Shi ^s   Chao, Yee ^s   Yen, Chia Jui ^s   Kara, Oguz ^s   Yalcin, Suayib ^s   Hochhauser, Daniel ^s   Chau, Ian ^s   Benson, Al ^s   Shankaran, Veena ^s   Shaib, Walid ^s   Philip, Philip ^s   Sharma, Vivek ^s   Siegel, Robert ^s   Sun, Weijing ^s   Wainberg, Zev ^s   George, Ben ^s   Bullock, Andrea ^s   Myrick, Samuel ^s   Faruol, Josephine ^s   Siegel, Richard ^s   Larson, Timothy ^s   Becerra, Carlos ^s   Ratnam, Suresh ^s   Richards, Donald A ^s   Riche, Stephen L ^s   more..

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b ISTANBUL UNIVERSITY   (Turkey)

^c Seoul National University College of Medicine   (South Korea)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^f University of Ulsan College of Medicine   (South Korea)

^g UNIVERSITY HOSPITAL OF PISA   (Italy)

^h INSTITUTE OF ONCOLOGY   (Poland)

ⁱ Instituto Oncológico Fundación Arturo López Pérez   (Chile)

^j Yonsei University College of Medicine   (South Korea)

^k AICHI CANCER CENTER HOSPITAL   (Japan)

^l Hematology Oncology Practice Eppendorf (HOPE)   (Germany)

^m UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁿ CHRISTIE HOSPITAL   (United Kingdom)

^o ADELAIDE AND MEATH HOSPITAL   (Ireland)

^p SHEBA MEDICAL CENTER   (Israel)

^q MERCK RESEARCH LABORATORIES   (United States)

^r YALE CANCER CENTER   (United States)

^s NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROPYRIMIDINE; PACLITAXEL; PEMBROLIZUMAB; PLATINUM DERIVATIVE; PROGRAMMED DEATH 1 LIGAND 1; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER MORTALITY; COLITIS; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS CANCER; FATIGUE; FEMALE; GASTROESOPHAGEAL JUNCTION CANCER; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; INFORMATION SYSTEM; INFUSION RELATED REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INTERACTIVE VOICE RESPONSE SYSTEM; INTERACTIVE WEB RESPONSE SYSTEM; MAJOR CLINICAL STUDY; MALE; MASS COMMUNICATION; MULTICENTER STUDY; NAUSEA; NEUTROPHIL COUNT; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREATITIS; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; SKIN MANIFESTATION; STOMACH CANCER; SURVIVAL TIME; TREATMENT DURATION; ADENOCARCINOMA; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; ESOPHAGUS TUMOR; GASTROESOPHAGEAL JUNCTION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; PATHOLOGY; STOMACH TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 85048592368     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)31257-1     Document Type: Article

References (28)

1. Ferlay, J, Soerjomataram, I, Dikshit, R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386.
2. National Comprehensive Cancer Network I. NCCN clinical practice guidelines in oncology. Gastric cancer (version 5.2017). https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf, 2017. (Accessed 9 February 2018)
3. Van Laethem, JL, Carneiro, F, Ducreux, M, et al. The multidisciplinary management of gastro-oesophageal junction tumours. European Society of Digestive Oncology (ESDO): expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona. Dig Liver Dis 48 (2016), 1283–1289.
4. Smyth, EC, Verheij, M, Allum, W, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:suppl 5 (2016), v38–v49.
5. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (version 4). Gastric Cancer 20 (2017), 1–19.
6. Bang, YJ, Van Cutsem, E, Feyereislova, A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376 (2010), 687–697.
7. Ribas, A, Tumor immunotherapy directed at PD-1. N Engl J Med 366 (2012), 2517–2519.
8. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513 (2014), 202–209.
9. Fuchs, CS, Doi, T, Jang, RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol, 2018 published online March 15. DOI:10.1001/jamaoncol.2018.0013.
10. Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
11. Wilke, H, Muro, K, Van Cutsem, E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15 (2014), 1224–1235.
12. Harrington, DP, Fleming, TR, A class of rank test procedures for censored survival-data. Biometrika 69 (1982), 553–566.
13. Bellmunt, J, de Wit, R, Vaughn, DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376 (2017), 1015–1026.
14. Hironaka, S, Ueda, S, Yasui, H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31 (2013), 4438–4444.
15. Wainberg, ZA, Jalal, SI, Muro, K, et al. KEYNOTE-059 update: efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patietns with advanced gastric or gastroesophageal (G/GEJ) cancer. Ann Oncol, 28(suppl 5), 2017 LBA28_PR.
16. Garon, EB, Rizvi, NA, Hui, R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
17. Daud, AI, Wolchok, JD, Robert, C, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol 34 (2016), 4102–4109.
18. Balar, AV, Castellano, D, O'Donnell, PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 18 (2017), 1483–1492.
19. Kang, YK, Boku, N, Satoh, T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390 (2017), 2461–2471.
20. Chang, L, Chang, M, Chang, HM, Chang, F, Microsatellite instability: a predictive biomarker for cancer immunotherapy. Appl Immunohistochem Mol Morphol 26 (2018), e15–e21.
21. Le, DT, Uram, JN, Wang, H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (2015), 2509–2520.
22. Le, DT, Durham, JN, Smith, KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357 (2017), 409–413.
23. Diaz, LA Jr, Marabelle, A, Delord, JP, et al. Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. J Clin Oncol, 35(15 suppl), 2017, 3071.
24. Panda, A, Mehnert, JM, Hirshfield, KM, et al. Immune activation and benefit from avelumab in EBV-positive gastric cancer. J Natl Cancer Inst 110 (2018), 316–320.
25. Motzer, RJ, Escudier, B, McDermott, DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
26. Ferris, RL, Blumenschein, G Jr, Fayette, J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375 (2016), 1856–1867.
27. Rittmeyer, A, Barlesi, F, Waterkamp, D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389 (2017), 255–265.
28. Duke Margolis Center for Health Policy. Public workshop: oncology clinical trials in the presence of nonproportional hazards. https://healthpolicy.duke.edu/events/public-workshop-oncology-clinical-trials-presence-non-proportional-hazards, Feb 5, 2018. (Accessed 5 March 2018)